Phio Pharmaceuticals Announces New Manufacturing Agreement

Phio Pharmaceuticals ( (PHIO) ) just unveiled an announcement.

On July 25, 2025, Phio Pharmaceuticals announced a new agreement with a U.S. manufacturer for the development and manufacturing of its lead compound, PH-762, marking a significant step in advancing its intratumoral program for treating cutaneous carcinomas. Additionally, Phio shared pathology results from its ongoing Phase 1b clinical trial, which evaluates the safety and tolerability of PH-762, as the company continues to enroll patients for the final cohort of this study.

The most recent analyst rating on (PHIO) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on Phio Pharmaceuticals stock, see the PHIO Stock Forecast page.

Spark’s Take on PHIO Stock

According to Spark, TipRanks’ AI Analyst, PHIO is a Neutral.

Phio Pharmaceuticals is struggling financially, with no revenue and consistent losses, significantly impacting its stock score. The technical indicators show mixed signals, with some short-term momentum but bearish long-term trends. The valuation is speculative due to negative earnings. The recent board appointment is a positive corporate event but has limited impact on overall financial health.

To see Spark’s full report on PHIO stock, click here.

More about Phio Pharmaceuticals

Phio Pharmaceuticals Corp. is a clinical-stage siRNA biopharmaceutical company focused on developing therapeutics using its proprietary INTASYL® gene silencing technology aimed at enhancing the immune system to combat cancer. The company’s lead clinical program involves the INTASYL compound PH-762, which targets the PD-1 gene associated with various skin cancers, including cutaneous squamous cell carcinoma, melanoma, and Merkel cell carcinoma.

Average Trading Volume: 563,148

Technical Sentiment Signal: Sell

Current Market Cap: $12.04M

For detailed information about PHIO stock, go to TipRanks’ Stock Analysis page.